Vanguard Group
OBIO icon

Vanguard Group’s Orchestra BioMed OBIO Stock Holding History

Vanguard Group’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$6.66M Buy
1,604,556
+122,681
+8% +$495K ﹤0.01% 3153
2025
Q3 		$3.68M Buy
1,481,875
+324,558
+28% +$895K ﹤0.01% 3375
2025
Q2 		$3.1M Sell
1,157,317
-150,449
-12% -$439K ﹤0.01% 3377
2025
Q1 		$5.6M Sell
1,307,766
-9,804
-0.7% -$48.7K ﹤0.01% 3124
2024
Q4 		$5.27M Buy
1,317,570
+7,767
+0.6% +$41.7K ﹤0.01% 3248
2024
Q3 		$6.73M Buy
1,309,803
+20,822
+2% +$136K ﹤0.01% 3137
2024
Q2 		$10.5M Buy
1,288,981
+60,634
+5% +$351K ﹤0.01% 2885
2024
Q1 		$6.47M Buy
1,228,347
+1,065
+0.1% +$7.22K ﹤0.01% 3186
2023
Q4 		$11.2M Sell
1,227,282
-18,827
-2% -$129K ﹤0.01% 2884
2023
Q3 		$10.9M Buy
1,246,109
+1,053,937
+548% +$7.09M ﹤0.01% 2835
2023
Q2 		$1.35M Buy
192,172
+88,043
+85% +$1.34M ﹤0.01% 3803
2023
Q1 		$2.04M Buy
+104,129
New +$1.21M ﹤0.01% 3666

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group's OBIO Position: Q4 2025 in Review

Vanguard Group increased its Orchestra BioMed (OBIO) stake by 8.3% in Q4 2025, buying an estimated $495K and bringing the position to 1,604,556 shares worth $6.66M. The position accounts for ﹤0.01% of the portfolio, ranked #3153.

Vanguard Group first reported a position in OBIO in Q1 2023 and has held it in 12 quarters since. The position peaked at $11.2M in Q4 2023. 63 funds tracked by Wall St. Rank hold OBIO as of Q4 2025.

  • Vanguard Group held 1,604,556 shares of Orchestra BioMed worth $6.66M as of Q4 2025.
  • Vanguard Group bought 122,681 Orchestra BioMed shares in Q4 2025, an estimated $495K.
  • Orchestra BioMed made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3153 holding.
  • Vanguard Group first reported a position in Orchestra BioMed in Q1 2023 and has held it in 12 quarters since.
  • Vanguard Group's Orchestra BioMed position peaked at $11.2M in Q4 2023.
  • 63 funds tracked by Wall St. Rank held Orchestra BioMed as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.